0001178913-21-003411.txt : 20211108 0001178913-21-003411.hdr.sgml : 20211108 20211108073543 ACCESSION NUMBER: 0001178913-21-003411 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211108 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 211386531 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 8-K 1 form8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2021

Chemomab Therapeutics Ltd.

(Exact name of Registrant as Specified in Its Charter)

State of Israel	001-38807	81-3676773
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

Kiryat Atidim, Building 7
Tel Aviv, Israel	6158002
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: +972-77-331-0156

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share	CMMB	Nasdaq Capital Market

Ordinary shares, no par value per share	N/A	Nasdaq Capital Market*

* Not for trading; only in connection with the registration of American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Conclusion of Engagement with Outgoing Interim Chief Financial Officer

On November 8, 2021, Chemomab Therapeutics Ltd. (the “Company”) and Ms. Sigal Fattal mutually agreed to conclude Ms. Fattal’s engagement as Interim Chief Financial Officer of the Company and its wholly-owned subsidiary Chemomab Ltd. (the “Subsidiary”). Ms. Fattal will continue to serve the Company and Subsidiary as a senior consultant to Mr. Marvin.

On November 8, 2021, the Company issued a press release announcing that, on November 8, 2021, it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The biographical information for Mr. Marvin appears below:

Donald Marvin, age 69, has more than 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations. Mr. Marvin served as Executive Vice President and Chief Financial Officer of Lodo Therapeutics from 2020 until 2021. He was previously Chairman, President and CEO of Concentric from 2014 to 2021. Prior to his positions at Concentric, Mr. Marvin was Managing Partner of Cairn Associates from 2006 until 2014. He was President and CEO of IdentiGEN from 2006 until 2009. Mr. Marvin was a co-founder of Orchid BioSciences, where he served as Chief Operating Officer, CFO and Senior Vice President of Corporate Development from 1997 to 2003, and President and Chief Executive Officer of Diatron Corporation from 1986 until 1994. Earlier in his career, Mr. Marvin held positions of increasing responsibility at Abbott, Boehringer Ingelheim, Bayer, and PepsiCo. Mr. Marvin earned a Bachelor of Science degree from The Ohio State University and an MBA from Iona College.

Mr. Marvin does not have a family relationship with any director or executive officer of the Company or person nominated or chosen by the Company to become a director or executive officer, and there are no arrangements or understandings between Mr. Marvin and any other person pursuant to which Mr. Marvin was selected to serve as Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company. There have been no transactions involving Mr. Marvin that would require disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended, or the Exchange Act.

Employment Agreement and Other Compensatory Arrangements

On November 8, 2021, the Chemomab Therapeutics Inc., the Company's wholly owned subsidiary, entered into an Executive Employment Agreement with Mr. Marvin (the “Agreement”). Mr. Marvin will receive an annual base salary of $460,000, and will be part of the Company’s bonus program with a yearly bonus potential of 45% of his base annual base salary, which bonus will be based on the achievement of mutually agreeable objectives to be determined by Mr. Marvin and the Chief Executive Officer of the Company. Additionally, Mr. Marvin will receive (i) 1.5% of the outstanding equity of the Company, which exercise price is based on the average of Company’s ADS market value over the 30 calendar days preceding November 8, 2021, and vesting over four years, (ii) an additional 0.5% of the outstanding equity of the Company for the achievement of strategic goals as agreed upon with the Compensation Committee and approved by the Board of Directors, (iii) a $25,000 signing bonus, and (iv) a 12-month initial severance package, which will increase by one month every two years that Mr. Marvin is employed by the Company, provided however that such amount does not exceed 18 months.

The foregoing description of the terms of the Agreement does not purport to be a complete description and is qualified in its entirety by reference to the Agreement, which is attached hereto as Exhibit 10.1 and is incorporated by reference in its entirety into this Item 5.02.

Item 7.01 Regulation FD Disclosure.

As described in Item 5.02 above, on November 8, 2021, the Company issued a press release announcing the appointment of Mr. Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Description
99.1	Press release issued by Chemomab Therapeutics Ltd. dated November 8, 2021

Exhibit 104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.

Date: November 8, 2021	By:	/s/ Dale Pfost
		Name: Dale Pfost
		Title: Chief Executive Officer

- 3 -

EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1

Exhibit 99.1

Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer,

Executive Vice President and Chief Operating Officer

Seasoned veteran brings Chemomab three decades of diverse life sciences industry experience

TEL AVIV, Israel, November 8, 2021 -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Donald R. Marvin has been named Chief Financial Officer, Executive Vice President and Chief Operating Officer. Mr. Marvin is a seasoned biotechnology executive with over 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations.

“Don’s deep expertise in building life sciences companies through a combination of organic growth and targeted strategic acquisitions will be invaluable as we advance our promising clinical programs and leverage the scientific foundation established by our founding team,” said Dale Pfost, PhD, Chief Executive Officer of Chemomab. “Don and I have worked separately and together to leverage innovative science, operational excellence and value-enhancing transactions to grow successful enterprises and create stakeholder value. I look forward to Don’s many contributions to Chemomab’s emerging leadership in developing novel therapeutics for fibrotic and inflammatory diseases with high unmet need.”

Until its acquisition earlier this year, Mr. Marvin served as Executive Vice President and Chief Financial Officer of Lodo Therapeutics. He was previously Chairman, President and CEO of Concentric, an agtech company that develops biological and essential plant nutrient inputs. Before Concentric, he was President and CEO of IdentiGEN, a leading provider of DNA-based solutions to the agriculture and food industries. Mr. Marvin was a co-founder of Nasdaq-traded Orchid BioSciences, a pioneer in human DNA testing, where he served as Chief Operating Officer, CFO and Senior Vice President of Corporate Development. A former New Jersey CFO of the Year, he has raised close to a half billion dollars in financings and has completed over a dozen successful mergers and acquisitions. Earlier in his career, Mr. Marvin held positions of increasing responsibility at Abbott, Boehringer Ingelheim, Bayer and PepsiCo. He has served on public and private company boards and regularly contributes columns to Forbes. Mr. Marvin earned a Bachelor of Science degree from The Ohio State University and an MBA from Iona College.

Mr. Marvin noted, “I am delighted to join Chemomab and reunite with Dale at a young company with so much promise. Chemomab has identified a unique immunotherapy target with the potential to generate a pipeline in a product, which I see as a solid base for building a world-class company. First and foremost, we will strive to continue to make the most of our current clinical trials, which reflect Chemomab’s 10-year commitment to discipline, drive and excellence in its scientific development activities. I also look forward to working with Chemomab’s strong executive team and its talented scientists to extend the company’s capabilities and take us to the next stage.”

Sigal Fattal, Chemomab’s interim CFO, will serve as a senior financial advisor to Mr. Marvin. Adi Mor, PhD, co-founder and CSO of Chemomab, commented, “We are delighted to have an executive with Don’s exceptional breadth of experience and established industry contacts join Chemomab. We also want to thank Sigal for her excellent work in building our finance organization and steering us through the transition to becoming a public company. We are very pleased that she will continue as a valued member of our senior team.”

About Chemomab Therapeutics Ltd.

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 safety and efficacy trials in patients with primary sclerosing cholangitis (PSC) and liver fibrosis, with a third Phase 2 trial in systemic sclerosis (SSc) expected to begin early in 2022.

For more information on Chemomab, visit www.chemomab.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab’s current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including: the uncertain and time-consuming regulatory approval process; risks related to Chemomab’s ability to correctly manage its operating expenses and its expenses; Chemomab’s plans to develop and commercialize its product candidates, focusing on CM-101; the timing of initiation of Chemomab’s planned clinical trials; the timing of the availability of data from Chemomab’s clinical trials; the timing of any planned investigational new drug application or new drug application; Chemomab’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab’s product candidates; Chemomab’s commercialization, marketing and manufacturing capabilities and strategy; Chemomab’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab’s and its business can be found under the caption “Risk Factors” and elsewhere in Chemomab’s filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts:

Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com

Media:

Barbara Lindheim

BLL Partners for Chemomab

Phone: +1-917-355-9234

blindheim@bllbiopartners.com

EX-101.SCH 3 cmmb-20211108.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 cmmb-20211108_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 cmmb-20211108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member] Ordinary shares, no par value per share [Member] EX-101.PRE 6 cmmb-20211108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00001.jpg begin 644 image00001.jpg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end XML 8 form8k_htm.xml IDEA: XBRL DOCUMENT 0001534248 2021-11-08 2021-11-08 0001534248 cmmb:AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember 2021-11-08 2021-11-08 0001534248 cmmb:OrdinarySharesNoParValuePerShareMember 2021-11-08 2021-11-08 false 00-0000000 0001534248 NASDAQ NASDAQ 8-K 2021-11-08 Chemomab Therapeutics Ltd. L3 001-38807 Kiryat Atidim, Building 7 Tel Aviv IL 6158002 972 77-331-0156 false false false false American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share CMMB Ordinary shares, no par value per share N/A true false XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Nov. 08, 2021
Entity Listings [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 08, 2021
Entity Registrant Name	Chemomab Therapeutics Ltd.
Entity Incorporation, State or Country Code	L3
Entity File Number	001-38807
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	Kiryat Atidim, Building 7
Entity Address, City or Town	Tel Aviv
Entity Address, Country	IL
Entity Address, Postal Zip Code	6158002
City Area Code	972
Local Phone Number	77-331-0156
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001534248
American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share
Trading Symbol	CMMB
Security Exchange Name	NASDAQ
Ordinary shares, no par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Ordinary shares, no par value per share
Trading Symbol	N/A
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://chemomab.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form8k.htm cmmb-20211108.xsd cmmb-20211108_def.xml cmmb-20211108_lab.xml cmmb-20211108_pre.xml exhibit_99-1.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "cmmb-20211108_def.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "cmmb-20211108_lab.xml" ] }, "presentationLink": { "local": [ "cmmb-20211108_pre.xml" ] }, "schema": { "local": [ "cmmb-20211108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 36, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 2, "memberStandard": 0, "nsprefix": "cmmb", "nsuri": "http://chemomab.com/20211108", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20211108to20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://chemomab.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20211108to20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "cmmb_AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member]" } } }, "localname": "AmericanDepositarySharesEachRepresentingTwenty20OrdinarySharesNoParValuePerShareMember", "nsuri": "http://chemomab.com/20211108", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "cmmb_OrdinarySharesNoParValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary shares, no par value per share [Member]" } } }, "localname": "OrdinarySharesNoParValuePerShareMember", "nsuri": "http://chemomab.com/20211108", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chemomab.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001178913-21-003411-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-21-003411-xbrl.zip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